|
Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy
Jae-Ho Yoon, Seok Lee
Korean J Intern Med. 2024;39(1):34-56. Published online January 1, 2024
Acute lymphoblastic leukemia (ALL) is one of the most rapidly changing hematological malignancies with advanced understanding of the genetic landscape, detection methods of minimal residual disease (MRD), and the development of immunotherapeutic agents with good clinical outcomes. The annual inciden..
|
|
|
Hemato-oncology
Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea: a multicenter retrospective study (KCSG LY20-06)
Jung Sun Kim, Tae Min Kim, Myoung Joo Kang, Sung Ae Koh, Hyunkyung Park, Seung-Hyun Nam, Jae Joon Han, Gyeong-Won Lee, Young Jin Yuh, Hee Jeong Lee, Jung Hye Choi
Korean J Intern Med. 2023;38(5):747-757. Published online June 26, 2023
Background/Aims: Little attention is paid to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Korea due to the rarity of the disease. With its rising incidence, we aimed to evaluate recent changes in treatment patterns and survival outcomes of patients with CLL/SLL.
Methods: A t..
|
|
|
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
Dong Won Baek, Han-Seung Park, Sang Kyun Sohn, Dae Young Kim, Inho Kim, Jae-Sook Ahn, Young Rok Do, Se Ryeon Lee, Hyeon-Seok Eom, Won-Sik Lee, Sung-Hyun Kim, Ho Sup Lee, Yoo Jin Lee, Joon Ho Moon, Je-Hwan Lee; Adult Acute Lymphoblastic Leukemia Working Party, the Korean Society of Hematology
Korean J Intern Med. 2023;38(5):734-746. Published online June 20, 2023
Background/Aims: We performed a prospective study to determine the efficacy and safety of rituximab including chemotherapy in CD20-positive acute lymphoblastic leukemia (ALL).
Methods: Patients with newly diagnosed ALL, aged ≥ 15 years, were eligible for the study if their leukemic blast cells in ..
|
|
|
The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
Mihee Kim, TaeHyung Kim, Seo-Yeon Ahn, Jun Hyung Lee, Ju Heon Park, Myung-Geun Shin, Sung-Hoon Jung, Ga-Young Song, Deok-Hwan Yang, Je-Jung Lee, Seung Hyun Choi, Mi Yeon Kim, Jae-Sook Ahn, Hyeoung-Joon Kim, Dennis Dong Hwan Kim
Korean J Intern Med. 2023;38(4):534-545. Published online June 9, 2023
Background/Aims: We evaluated the role of next-generation sequencing (NGS)-based disease monitoring for elderly patients diagnosed with acute myeloid leukemia (AML) who received decitabine therapy.
Methods: A total of 123 patients aged > 65 years with AML who received decitabine were eligible. We an..
|
|
|
Long-term follow-up results of cytarabine-containing chemotherapy for acute promyelocytic leukemia
Young Hoon Park, Dae-Young Kim, Yeung-Chul Mun, Eun Kyung Cho, Jae Hoon Lee, Deog-Yeon Jo, Inho Kim, Sung-Soo Yoon, Seon Yang Park, Byoungkook Kim, Soo-Mee Bang, Hawk Kim, Young Joo Min, Jae Hoo Park, Jong Jin Seo, Hyung Nam Moon, Moon Hee Lee, Chul Soo Kim, Won Sik Lee, So Young Chong, Doyeun Oh, Dae Young Zang, Kyung Hee Lee, Myung Soo Hyun, Heung Sik Kim, Sung-Hyun Kim, Hyukchan Kwon, Hyo Jin Kim, Kyung Tae Park, Sung Hwa Bae, Hun Mo Ryoo, Jung Hye Choi, Myung-Ju Ahn, Hwi-Joong Yoon, Sung-Hyun Nam, Bong-Seog Kim, Chu-Myong Seong
Korean J Intern Med. 2022;37(4):841-850. Published online June 28, 2022
Background/Aims: We evaluated the feasibility and long-term efficacy of the combination of cytarabine, idarubicin, and all-trans retinoic acid (ATRA) for treating patients with newly diagnosed acute promyelocytic leukemia (APL).
Methods: We included 87 patients with newly diagnosed acute myeloid l..
|
|
|
Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
Yoo Jin Na, Eun Sang Yu, Dae Sik Kim, Dae-Hee Lee, Sang Cheul Oh, Chul Won Choi
Korean J Intern Med. 2021;36(Suppl 1):S196-S206. Published online April 3, 2020
Background/Aims: Nilotinib is used for treating patients with imatinib-sensitive or -resistant chronic myeloid leukemia (CML); however, nilotinib-resistant cases have been observed in recent years. In addition, a considerable number of patients receiving nilotinib developed diabetes. Metformin is a ..
|
|
|
Pediatric-inspired regimen with late intensification and increased dose of L-asparaginase for adult acute lymphoblastic leukemia: the KALLA 1406/1407 study
Dong Won Baek, Dae Young Kim, Sang Kyun Sohn, Youngil Koh, Sung-Hoon Jung, Ho-Young Yhim, Yunsuk Choi, Joon Ho Moon
Korean J Intern Med. 2021;36(6):1471-1485. Published online September 24, 2021
Background/Aims: The objective of this study was to evaluate the efficacy and feasibility of the pediatric-inspired regimen of the adult acute lymphoblastic leukemia (ALL) Working Party, the Korean Society of Hematology.
Methods: Data of 99 patients with newly diagnosed ALL, who were treated with t..
|
|
|
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia
Yundeok Kim, Tae-Hwa Go, Jaeyeon Jang, Jii Bum Lee, Seung Taek Lim, Kwang Yong Shim, Jong In Lee, Jee Hyun Kong
Korean J Intern Med. 2021;36(6):1450-1458. Published online November 1, 2021
Background/Aims: Adherence to tyrosine kinase inhibitors (TKIs) has become a critical aspect of care in chronic myeloid leukemia (CML). We aimed to examine the association of TKI adherence with overall survival (OS) outcomes in Korean patients diagnosed with CML and treated with TKIs using data from..
|
|
|
Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia
Heejoo Han, Ja Min Byun, Dong-Yeop Shin, Sung-Soo Yoon, Youngil Koh, Junshik Hong, Inho Kim, Chansup Lee, Hyeonjoo Yoo, Hongseok Yun, Man Jin Kim, Sung Im Cho, Moon-Woo Seong, Sung Sup Park
Korean J Intern Med. 2021;36(2):401-412. Published online August 20, 2020
Background/Aims: Understanding leukemic stem cell (LSC) is important for acute myeloid leukemia (AML) treatment. However, association of LSC with patient prognosis and genetic information in AML patients is unclear.
Methods: Here we investigated the associations between genetic information and the ..
|
|
|
Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study
Yunsuk Choi, Jung-Hee Lee, Chul Won Jung, Jae-Cheol Jo, Jin Seok Kim, Inho Kim, Silvia Park, June-won Cheong, Sang-Hyuk Park, Sung-Yong Kim, Hong-Ghi Lee
Korean J Intern Med. 2021;36(1):194-204. Published online April 14, 2020
Background/Aims: Compared with Western countries, chronic lymphocytic leukemia (CLL) rarely occurs in Asia and has different clinical characteristics. Thus, we aimed to evaluate the clinical characteristics, treatment outcomes, and prognostic significance of Korean patients with CLL.
Methods: We re..
|
|
|
Small RNA sequencing profiles of mir-181 and mir-221, the most relevant microRNAs in acute myeloid leukemia
Yun-Gyoo Lee, Inho Kim, Somi Oh, Dong-Yeop Shin, Youngil Koh, Keun-Wook Lee
Korean J Intern Med. 2019;34(1):178-183. Published online November 27, 2017
Background/Aims: To evaluate and select microRNAs relevant to acute myeloid leukemia (AML) pathogenesis, we analyzed differential microRNA expression by quantitative small RNA next-generation sequencing using duplicate marrow samples from individual AML patients.
Methods: For this study, we obtaine..
|
|
|
|
|
Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia
Eunjung Yim, Yeon-Geun Choi, Yoon-Jeong Nam, Jain Lee, Jeong-A Kim
Korean J Intern Med. 2018;33(2):446-448. Published online March 10, 2016
|
|
|
|
|
An isolated cardiac relapse after allogeneic hematopoietic stem cell transplantation for acute
lymphoblastic leukemia
Kiju Chang, Dae-Young Kim, Kyoo-Hyung Lee, Jooryung Huh, Joon-Won Kang, Dong Yeol Shin, Dae-Hee Kim
Korean J Intern Med. 2017;32(4):753-757. Published online February 2, 2016
|
|
|
Hemato-oncology
Targeting the CXCL12/CXCR4 axis in acute myeloid leukemia: from bench to bedside
Byung-Sik Cho, Hee-Je Kim, Marina Konopleva
Korean J Intern Med. 2017;32(2):248-257. Published online February 21, 2017
The interactions between the cancerous cells of acute myeloid leukemia (AML) and the bone marrow (BM) microenvironment have been postulated to be important for resistance to chemotherapy and disease relapse in AML. The chemokine receptor CXC chemokine receptor 4 (CXCR4) and its ligand, CXC motif li..
|
|
|
BCR-ABL1 transcripts (MR4.5) at post-transplant 3 months as an early predictor for long-term outcomes in chronic myeloid leukemia
Sung-Eun Lee, Soo Young Choi, Soo-Hyun Kim, Hye-Young Song, Hea-Lyun Yoo, Mi-Young Lee, Ki-Hoon Kang, Hee-Jeong Hwang, Eun-Jung Jang, Dong-Wook Kim
Korean J Intern Med. 2017;32(1):125-136. Published online June 22, 2016
Background/Aims: The aim of this study was to identify the role of BCR-ABL1 transcript level as a predictor for post-transplant relapse and outcome in patients who underwent allogeneic stem cell transplantation (SCT) for chronic phase (CP) chronic myeloid leukemia (CML). Methods: Of 101 patients rec..
|
|
|
Chronic lymphocytic leukemia: a clinical review including Korean cohorts
Young-Woo Jeon, Seok-Goo Cho
Korean J Intern Med. 2016;31(3):433-443. Published online April 5, 2016
Only 5th decade ago, chronic lymphocytic leukemia (CLL) was only recognized as disease group of presenting features like peripheral lymphocytosis, organomegaly including of splenomegaly. As understanding of disease biology and molecular diagnostic tools are getting improved gradually, characterizati..
|
|
|
Mixed-phenotype acute leukemia treated with decitabine
Ji-Young Lee, Sang-min Lee, Ja-Young Lee, Ki-Hyang Kim, Moon-Young Choi, Won-Sik Lee
Korean J Intern Med. 2016;31(2):406-408. Published online February 15, 2016
|
|
|
Hemato-oncology
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
Dae Sik Kim, Yoo Jin Na, Myoung Hee Kang, Soo-Young Yoon, Chul Won Choi
Korean J Intern Med. 2016;31(2):357-366. Published online February 15, 2016
Background/Aims: The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate. Nevertheless, resistance to imatinib has been observed, and a substantial number of patients need alternative treatment ..
|
|
|
